Wish I could disclaim interest at $3 plus and blame it all on Dr. Tracy, but, alas, this thread probably documents my early enthusiasm. :-)
I liked them _before_ they (1) took memantine into the phase II trial (NIH-sponsored) for AIDS-related dementia, (2) got the data for CRF/peritumoral brain edema, and (3) got the additional data with Dynorphin A for the management of post-surgical pain (morphine adjuvant). During this time, Stuart Lipton has also been pursuing second and third generation molecules that are memantine and nitroglycerine analogs. So, a market cap of $16 million is crazy (IMO), crazy (IMO), crazy (IMO)!
Unfortunately, the CRF trial for RA ate up a lot of burn. Overall, however, yes, I believe that NTII is due some respect. I'll find and repost the press release regarding the phase II NIH trial. Given the exacting design of the trial and the long history of memantine use in Europe, we could see an NDA derive directly from this trial. Opinions?
Rick |
